What compounding changes

Ask why this preparation is being proposed

With compounding, a doctor, pharmacist, or registered facility prepares the medicine instead of supplying the product finished by a drug company. FDA's September 2026 framework allowed a role for compounding when an approved medicine could not meet a patient's medical need or was not commercially available. Ask the prescriber to explain the need in your case before comparing prices or delivery arrangements.

A useful answer describes the proposed difference and why it matters to you. Ask for that explanation in writing. Keep it beside the ingredient name and the pharmacy's name. A general claim about personal care does not give the same information as a reason tied to your assessment.

Separate compounding from approval

In September 2026, FDA had not approved compounded medicines, including those from well-run pharmacies. There is no FDA review before marketing to verify the quality, effectiveness, or safety of those drugs. The federal agency that reviews drugs uses the abbreviation FDA for Food and Drug Administration. Ask how the professional explains that limit when discussing the proposed medicine.

As of September 2026, FDA called it false or misleading to claim that studies proved a compounded drug gave the same results as an approved medicine. It also rejected describing a compounded preparation as an approved generic medicine. An approved generic is a version of a brand medicine with its own FDA approval. By November 3, 2026, liraglutide had approved generics, including some for weight management. A semaglutide application had only tentative approval, which did not allow sales. There was no semaglutide or tirzepatide generic that could be sold in the United States. That word has a particular meaning; it is not just a way to say that a preparation contains a familiar ingredient.

The kind of compounder matters

In September 2026, section 503A covered drugs made for a named person with a prescription, when its other conditions were met. An outsourcing facility is a compounder that chooses FDA registration under section 503B and makes sterile medicines in batches, often for clinics or hospitals. The business need not be licensed as a pharmacy or get prescriptions naming each person who would receive the medicine. Sterile means free of living germs. The section numbers are names for different parts of the law.

For an outsourcing facility, registration was not FDA approval of the place or its drugs in September 2026. Ask which kind of compounder is involved and where you can check the record. You do not need to interpret the section number as a quality score.

A shortage has a specific meaning

A pharmacy with empty shelves does not by itself establish a national shortage on the FDA list. The FDA shortage-list check in September 2026 returned no listing for either tirzepatide or semaglutide injection. FDA rules recorded in September 2026 restricted routine copies of medicines already on the market. Under section 503A, a prescriber could identify a change that made a significant difference for a particular person. Ask what basis applies to the exact proposal rather than relying on an old shortage headline.

An older article may describe a different point in that history. Read the date as part of the claim. A proposed rule, an advisory discussion, and a final rule are different records. If a service cites one, ask it to identify the document and explain how it applies.

A withdrawn request is not permission

BPC-157 was among withdrawn requests on the page FDA described as current as of April 22, 2026. The request was for permission to use an ingredient in compounding; the people or groups who submitted it had taken it back. That entry still carried the agency's safety concerns. Separately, the Department of Health and Human Services, or HHS, announced a draft policy on October 30, 2026. The policy named semax, epitalon and KPV. TB-500, BPC-157 and MOTS-c made up the rest of its six covered peptides. For an individual patient's prescription, HHS said it did not intend to pursue enforcement against physicians and state-licensed pharmacies compounding one of these peptides, if every condition was met. Neither the withdrawal nor this nonbinding draft made the peptides FDA-approved. None of these six peptides appeared on FDA's 503A bulks list, the official list of additional compounding ingredients, as of November 3, 2026. The draft covers single-ingredient preparations only; blends and 503B outsourcing facilities are excluded. FDA published no individual withdrawal date for that entry. A request being taken back is different from a medicine being removed from sale for safety reasons. Ask for the original rule behind any claim that an ingredient is now allowed.

Before moving on, make sure you have the product name, the reason for compounding, the compounder's identity, and the original source offered for its status. Take an unresolved point back to the prescriber. The next chapter helps with reading the evidence behind a claim.